TaiwanBiotech & Genomic Medicine▲
TaiMed Biologics receives TFDA drug license collection notice for Trogarzo
TaiMed Biologics has received a Drug License Collection Notice from the Taiwan Food and Drug Administration for its HIV therapy Trogarzo, marking the final step before commercial launch in Taiwan. The company's commercialization partner, Orient EuroPharma, will now complete the required procedures to obtain the drug license. Trogarzo, the world's first and only CD4-directed monoclonal antibody approved for HIV, had already received a TFDA Approval Letter in June. TaiMed entered into an exclusive commercialization and distribution agreement with Orient EuroPharma for the Taiwan market in May 2024. The company also reported a return to profitability in the first quarter of this year, driven by Trogarzo's global commercialization.